Can-Fite BioPharma Ltd. filed a Form D with the Securities and Exchange Commission on 2026-09-10.
Can-Fite BioPharma Ltd. filed a Form D notice of an exempt securities offering with the SEC on September 10, 2026. The filing reports $8.31M sold. Its industry group is Pharmaceuticals. It names Motti Farbstein (Chief Executive Officer, Chief Financial Officer and Chief Operating Officer), Pnina Fishman (Executive Chairman of the Board and Chief Scientific Officer), Sari Fishman (Vice President of Business Development) (SEC Form D, September 10, 2026).
Sell to companies like Can-Fite BioPharma Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2026-09-10 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Can-Fite BioPharma Ltd.
Free to see. No signup.
More on the people and the money behind Can-Fite BioPharma Ltd., from the filings we hold.
Pharmaceuticals raises filed within 90 days of this one, largest first.
Get an email when Can-Fite BioPharma Ltd. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Can-Fite BioPharma Ltd. raises, hires or launches. No email unless you switch it on.
Watch Can-Fite BioPharma Ltd. →Get the full cited report on Can-Fite BioPharma Ltd.
What the filing shows about Can-Fite BioPharma Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Can-Fite BioPharma Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Can-Fite BioPharma Ltd. See pricing
Trailing twelve months. 157 filings in Pharmaceuticals, totalled by week. The dot is this raise, $8.31M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Issuer expects to use any proceeds for funding research and development and clinical trials and for other working capital and general corporate purposes.. No proceeds are expected to be paid to executive officers, directors, or promoters.
By form type: 6-K ×542 · EFFECT ×40 · CORRESP ×29 · 424B3 ×28 · POS AM ×26 · UPLOAD ×23 · SC 13G/A ×19 · D ×15, and others.
| Form | Filed | On EDGAR |
|---|---|---|
| D | 2026-09-10 | open |
| 6-K | 2026-09-09 | open |
| POS AM | 2026-09-08 | open |
| POS AM | 2026-09-08 | open |
| 6-K | 2026-09-08 | open |
| 6-K | 2026-09-03 | open |
| 6-K | 2026-09-02 | open |
| 6-K | 2026-09-02 | open |
| F-3 | 2026-08-28 | open |
| 6-K | 2026-08-17 | open |
What the filing shows about Can-Fite BioPharma Ltd.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Can-Fite BioPharma Ltd.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Can-Fite BioPharma Ltd. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The 10 most recent of 856 filings on CIK 0001536196, filed as Can-Fite BioPharma Ltd.. Read from the SEC's own submissions feed for this issuer, not from a third party. Incorporated in L3. Full history on sec.gov.
Checked away from the filing. What is below does not come from the record on sec.gov.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and…
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer.
Motti Farbstein is named as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer on the Form D that Can-Fite BioPharma Ltd. filed with the SEC on 10 September 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
Pnina Fishman is named as Executive Chairman of the Board and Chief Scientific Officer on the Form D that Can-Fite BioPharma Ltd. filed with the SEC on 10 September 2026, one of 7 people that filing names.
On the filing as: Executive Officer.
Sari Fishman is named as Vice President of Business Development on the Form D that Can-Fite BioPharma Ltd. filed with the SEC on 10 September 2026, one of 7 people that filing names.
Guy Regev is named as Director on the Form D that Can-Fite BioPharma Ltd. filed with the SEC on 10 September 2026, one of 7 people that filing names.
Abraham Sartani is named as Director on the Form D that Can-Fite BioPharma Ltd. filed with the SEC on 10 September 2026, one of 7 people that filing names.
Yoseph Bornstein is named as Director on the Form D that Can-Fite BioPharma Ltd. filed with the SEC on 10 September 2026, one of 7 people that filing names.
Ilan Tamir is named as Director on the Form D that Can-Fite BioPharma Ltd. filed with the SEC on 10 September 2026, one of 7 people that filing names.
7 people named on the filing — 3 holding an executive role and 4 as directors only.
Named as of the 2026-09-10 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Can-Fite BioPharma Ltd.You get an alert in MentionFox the next time this company shows up.
If you're behind Can-Fite BioPharma Ltd.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-09-25 (ir.canfite.com).
Each opens in a new tab, filled in for Can-Fite BioPharma Ltd.. With no account yet, you sign up free and land on the result.
On these lists: Outside the US raises, week of 2026-09-07
https://mentionfox.com/funding/can-fite-biopharma-ltd-form-d-098844